NCT05844332

LUTATHERA Injection General Use Result Survey

LUTATHERA Injection General Use Result Survey (Somatostatin Receptor-positive Neuroendocrine Tumor, CAAA601A11401)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 347 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This study was a multicenter observational study with a central registration system and all-case surveillance system without a control group.

Detailed description

From the date of the first dose of this drug until 40 weeks after the date of the last dose (64 weeks if 4 doses are administered 8 weeks apart). For patients who discontinue treatment with this drug during the observation period, necessary variables were examined until 40 weeks after the last dose of this drug during the observation period and recorded in the case report forms (CRF).

Conditions

• Somatostatin Receptor-positive Neuroendocrine Tumor

Interventions

Type	Name	Description
OTHER	LUTATHERA	There was no treatment allocation. Patients administered LUTATHERA by prescription could be enrolled.

Timeline

• Start date: 2021-12-17
• Primary completion: 2024-06-27
• Completion: 2024-06-27
• First posted: 2023-05-06
• Last updated: 2025-12-22

Locations

46 sites across 1 country: Japan